Overview
Lobbying Costs
250,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
3 Fte (4)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
European Society for Radiotherapy and Oncology (ESTRO)
EU Transparency Register
114144232470-50 First registered on 21 Sep 2018
Goals / Remit
ESTRO’s new vision statement for 2030 ‘Radiation Oncology. Optimal Health for All, Together.’ emphasizes the ambition of the Society to further reinforce radiation oncology as core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it.
To do so, it will actively focus on translating science and evidence into practice. It will continue to support all radiotherapy professionals in their needs of continuous professional development. The needs of a growing Society in terms of governance and leadership will actively be addressed. The Society will also increasingly embrace its role in policy, through a broadening network of partnerships with all relevant stakeholders.
Without calling for a disruptive change with the past, but conscious of the challenges ahead, the ESTRO vision statement for 2030 is ambitious, expansive, inclusive and open to the future.
https://www.estro.org/ESTRO/media/ESTRO/About/190417-ESTRO-Vision-Paper-2030.pdf
To fulfil its mission ESTRO will:
-Develop and promote standards of education in radiotherapy and clinical oncology
-Promote standards of practice in radiotherapy, clinical oncology and related subjects
-Stimulate the exchange of scientific knowledge in all related fields
-Strengthen the clinical specialty of radiotherapy and clinical oncology in relation to other specialties and professions involved in cancer management
-Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
-Facilitate research and development in radiotherapy, clinical oncology and related subjects.Main EU files targeted
• CANCON www.cancercontrol.eu
• IPAAC Innovative Partnership for Actions Against Cancer https://www.ipaac.eu
• JARC Joint Action on Cancer (together with SIOPE https://www.siope.eu/)
• ERN European Reference Network http://www.ern-rnd.eu/
• IMI Innovative Medicines Agency https://www.imi.europa.eu/
• COUNCIL DIRECTIVE 2013/59/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/ ARTICLE 63 + 78
• Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare
• Directive 2013/35/EU of the European Parliament and of the Council of 26 June 2013 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields)
• Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU
• Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
• Inputs provided on the ESCO forum, regarding the professions working in radiotherapy
• Proposal for a thematic network on EU Health Policy PlatformAddress
Head Office
Rue Martin V. 40
Brussels 1200
BELGIUM -
People
Total lobbyists declared
4
Employment time Lobbyists 100% 2 75% 1 25% 1 Lobbyists (Full time equivalent)
3
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
• Christine Verfaillie Managing Director Education and Science / Viviane Van Egten Education Manager 25%
• Chiara Gasparotto Director of Policy & Partnership 75%
• Noémie Defourny Health Economist 100%
• Gabriella Axelsson Public Affairs project manager 100%Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
III - Non-governmental organisations
Subcategory
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
None declared
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
250,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Projects:
- HERO project, Health Economics in Radiation Oncology. https://www.estro.org/about-us/health-economics-in-radiation-oncology---hero/hero
- ROSEIS, Radiation Oncology Safety Education and Information System. https://roseis.estro.org
Communication activities:
- ESTRO SYMPOSIUM AT THE EUROPEAN PARLAMENT: "Radiotherapy Cures Cancer Today", organised on the 5th Dec 2017. https://www.estro.org/binaries/content/assets/estro/about/news/event-report-radiotherapy-cures-cancer-today-5th-december-2017.pdf
Publications:
- Kazmierska J, Jornet Sala N, Leech M, et al. 2019. Radiotherapy: seizing the opportunity in cancer care. Tumori Journal 2019, Vol. 105(2S) 3–59
- Training Requirements in Radiation Oncology https://www.uems.eu/__data/assets/pdf_file/0015/44430/UEMS-2013.20-European-Training-Requirements-in-Radiation-Oncology.pdf
- Lievens Y, Grau C. Health economics in radiation oncology: introducing the ESTRO HERO project. Radiother Oncol 2012 Apr;103(1):109-12
- Lievens Y, Defourny N, Coffey M, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 2014;112:178– 86
- Grau C, Defourny N, Malicki J, et al. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 2014;112:155–64
- Dunscombe P, Grau C, Defourny N, et al. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey., Radiother Oncol. 2014 Aug;112(2):165-77
- Lievens Y, Dunscombe P, Defourny N, et al. HERO (Health Economics in Radiation Oncology): a pan-European project on radiotherapy resources and needs. C. Clin Oncol (R Coll Radiol). 2015 Feb;27(2):115-24.
- Borras JM, Barton M, Grau C, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population-based analysis by the ESTRO-HERO project. Radiother Oncol. 2015 Jul;116(1):45-50.
- Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015 Jul;116(1):38-44
- Borras, J. M., Lievens, Y., Barton, M., et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 119(1), 5-11.
- Defourny, N., Dunscombe, P., Perrier, L., et al. Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 121(3), 468-474.
-Lievens, Yolande; Gospodarowicz, Mary; Grover, Surbhi; Jaffray, David; Rodin, Danielle; Torode, Julie; Yap, Mei Ling; Zubizarreta, Eduardo; GIRO Steering and Advisory Committees - Global impact of radiotherapy in oncology: Saving one million lives by 2035, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 125, Issue: 2, Page: 175-177 Publication Year: 2017
-Coffey M, Technical Innovations & Patient Support in Radiation Oncology. Elsevier BV ISSN: 2405-6324, Vol: 1, Page: 16-17 Publication Year: 2017
- Borras, Josep M; Grau, Cai; Corral, Julieta; Wong, Karen; Barton, Michael B; Ferlay, Jacques; Bray, Freddie; Lievens, Yolande, Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 126, Issue: 2, Page: 198-204 Publication Year: 2018Other activities
None declared
Meetings
Meetings
None declared